Vonoprazan fumarate composition and preparation method thereof, and Vonoprazan fumarate tablet and preparation method thereof

By adding stabilizers such as tartaric acid and fillers to the fumaric acid vonora fumaric acid composition, combining binder and disintegrant, vonora fumaric acid tablets are prepared, and the stability is improved through the coating layer, and the solution is solved The problem of insufficient stability of vonora fumarate has achieved the safety and effectiveness of drugs and the adaptability of industrial production.

CN119033781APending Publication Date: 2024-11-29SHANDONG LUKANG PHARMA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411198614.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Due to the low pKa value of vonora fumarate, its stability is insufficient. The chain organic acid fumarate used in the prior art is not high, which further reduces the acidity and stability of the drug.

Method used

Using vonora fumarate composition, add stabilizers such as tartaric acid, maleic acid or malonic acid, combined with fillers, binders and disintegrants, prepare vonora fumarate tablets and pass packaging The clothing layer further improves stability.

Benefits of technology

Without changing the acidity of the drug, the stability of the vonolasan fumarate composition and tablets is significantly improved, the problem of light sensitivity is overcome, the safety and effectiveness of the drug is ensured, and the preparation process is simplified. Suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005018564580000011
    Figure BDA0005018564580000011
  • Figure BDA0005018564580000061
    Figure BDA0005018564580000061
  • Figure BDA0005018564580000071
    Figure BDA0005018564580000071
Patent Text Reader

Abstract

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a fumaric acid vonoprazan composition and a preparation method thereof, and a fumaric acid vonoprazan tablet and a preparation method of the fumaric acid vonoprazan tablet. By adding the specific stabilizer and the adhesive, free radicals in a system are removed by the stabilizer on the premise of not changing the acidity of the medicine, so that the high-stability Vonoprazan fumarate composition is obtained, the instability caused by sensitivity of Vonoprazan fumarate to light is overcome, and the safety and effectiveness of taking by a patient are ensured. The preparation method of the Vonoprazan fumarate composition provided by the invention is simple in steps, convenient to operate and suitable for industrial large-scale production. According to the fumaric acid vonorbitan tablet provided by the invention, the fumaric acid vonorbitan composition is adopted as the tablet core, the acidity of the pharmaceutical composition is not changed, and a coating layer is used as an auxiliary material, so that the stability of the fumaric acid vonorbitan tablet in the preparation and storage processes is further improved, and the safety and effectiveness of the medicine are ensured.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a vonoprazan fumarate composition and a preparation method thereof, and a vonoprazan fumarate tablet and a preparation method thereof. Background Art

[0002] Vonoprazan fumarate, chemical name is 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrol-3-yl]-N-methylmethylamine monofumarate, molecular formula is C 17 H 16 FN3O2S·C4H4O4, the structural formula is as follows:

[0003]

[0004] Vonoprazan fumarate is a novel acid-suppressing drug that can + / K + -K of ATPase + channel, competitively blocks K + It binds to the enzyme and stays in the gastric wall cells for a long time, thereby quickly inhibiting the secretion of gastric acid. It can be used to treat digestive system diseases such as gastric ulcer, duodenal ulcer and reflux esophagitis.

[0005] Chinese patent CN 102743330A discloses a pharmaceutical composition, which achieves the effect of inhibiting decomposition products during the stability period of the pharmaceutical composition by adding chain organic acid fumaric acid. However, the pKa of vonoprazan fumarate itself is 4.6, and the pKa of the chain organic acid fumaric acid used in the patent is not higher than 4.0, which will change the acidity of the drug and reduce the stability of the drug. Summary of the invention

[0006] The purpose of the present invention is to provide a vonoprazan fumarate composition and a preparation method thereof, and a vonoprazan fumarate tablet and a preparation method thereof. The vonoprazan fumarate composition provided by the present invention improves its stability without changing the acidity of the drug itself.

[0007] In order to achieve the above object, the present invention provides the following technical solutions:

[0008] The invention provides a vonoprazan fumarate composition, comprising vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant and a lubricant; the stabilizer comprises one or more of tartaric acid, maleic acid, malonic acid and tartaric acid.

[0009] Preferably, the vonoprazan fumarate composition comprises, by weight percentage, 5-15 wt% vonoprazan fumarate, 0.05-1.0 wt% stabilizer, 70-90 wt% filler, 1-3 wt% binder, 2-8 wt% disintegrant and the balance lubricant.

[0010] Preferably, the binder includes one or more of cellulose, starch and povidone; the cellulose includes one or more of hydroxypropyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose.

[0011] The present invention also provides a method for preparing the vonoprazan fumarate composition described in the above scheme, comprising the following steps:

[0012] The vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant and a lubricant are first mixed to obtain a vonoprazan fumarate composition.

[0013] Preferably, the first mixing is: mixing vonoprazan fumarate, a stabilizer, a filler, a binder and a disintegrant to obtain a second mixture, and mixing the second mixture with a lubricant.

[0014] The present invention also provides a vonoprazan fumarate tablet, comprising a tablet core and a coating layer coated on the surface of the tablet core; the tablet core is the vonoprazan fumarate composition described in the above scheme or the vonoprazan fumarate composition obtained by the preparation method described in the above scheme.

[0015] Preferably, the tablet core accounts for 95.5-97.5% of the mass percentage of the vonoprazan fumarate tablets; and the coating layer accounts for 2.5-4.5% of the mass percentage of the vonoprazan fumarate tablets.

[0016] The present invention also provides a method for preparing the vonolazepam fumarate tablets described in the above scheme, comprising the following steps:

[0017] (1) mixing vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant, a lubricant and water and then tableting to obtain a tablet core;

[0018] (2) coating the tablet core to obtain vonolazepine fumarate raw tablets.

[0019] Preferably, the tabletting pressure is 7.50-11.00 kg, and the pressure holding time is 2-7 s.

[0020] Preferably, the coating is performed by mixing coating powder and water to obtain a coating solution, and then coating the coating solution on the surface of the tablet core while drying.

[0021] The present invention provides a vonoprazan fumarate composition. The present invention adds a specific stabilizer, and the stabilizer removes free radicals in the system without changing the acidity of the drug itself, thereby obtaining a vonoprazan fumarate composition with high stability, overcoming the instability of vonoprazan fumarate caused by photosensitivity, and ensuring the safety and effectiveness of patients taking the composition.

[0022] The present invention also provides a method for preparing the vonoprazan fumarate composition of the above scheme. The preparation method provided by the present invention has simple steps, convenient operation, and is suitable for industrial large-scale production.

[0023] The present invention also provides a fumarate vonoprazan tablet. The fumarate vonoprazan tablet provided by the present invention adopts the fumarate vonoprazan composition of the above scheme as the tablet core, does not change the acidity of the drug composition itself, and is assisted by a coating layer, which further improves the stability of the fumarate vonoprazan tablet during preparation and storage, ensuring the safety and effectiveness of the drug.

[0024] The present invention also provides a method for preparing the vonoprazan fumarate tablets described in the above scheme. The preparation method provided by the present invention adopts a two-step method, has fewer production links, reduces the probability of failure, has good process stability, and has industrial prospects. DETAILED DESCRIPTION

[0025] The invention provides a vonoprazan fumarate composition, comprising vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant and a lubricant; the stabilizer comprises one or more of tartaric acid, maleic acid, malonic acid and tartaric acid.

[0026] In terms of mass percentage, the vonoprazan fumarate composition provided by the present invention preferably comprises 5 to 15 wt % of vonoprazan fumarate, more preferably 7 to 12 wt %, and further preferably 9 to 10 wt %.

[0027] In terms of weight percentage, the vonoprazan fumarate composition provided by the present invention preferably includes 0.05 to 1.0 wt % of a stabilizer, more preferably 0.1 to 0.8 wt %, and further preferably 0.3 to 0.5 wt %.

[0028] In the present invention, the stabilizer is preferably tartaric acid.

[0029] In terms of mass percentage, the vonoprazan fumarate composition provided by the present invention preferably includes 70 to 90 wt % of filler, more preferably 74 to 86 wt %, and further preferably 78 to 82 wt %.

[0030] In the present invention, the filler preferably includes one or more of dextrin, lactose, microcrystalline cellulose, starch and mannitol.

[0031] In terms of mass percentage, the vonoprazan fumarate composition provided by the present invention preferably includes 1 to 3 wt % of a binder, more preferably 1.4 to 2.7 wt %, and further preferably 1.8 to 2.4 wt %.

[0032] In the present invention, the binder preferably includes one or more of cellulose, starch and povidone; the cellulose preferably includes one or more of hydroxypropyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose; and the starch is preferably corn starch.

[0033] In terms of weight percentage, the vonoprazan fumarate composition provided by the present invention preferably includes 2 to 8 wt % of a disintegrant, more preferably 3 to 7 wt %, and even more preferably 4 to 6 wt %.

[0034] In the present invention, the disintegrant preferably includes one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and sodium carboxymethyl starch.

[0035] Calculated by mass percentage, the vonoprazan fumarate composition provided by the present invention preferably includes a lubricant balance.

[0036] In the present invention, the lubricant preferably includes one or more of magnesium stearate, talc, polyethylene glycol and micro powder silica gel.

[0037] The present invention also provides a method for preparing the vonoprazan fumarate composition described in the above scheme, comprising the following steps:

[0038] Vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant and a lubricant are mixed (referred to as the first mixing) to obtain a vonoprazan fumarate composition.

[0039] In the present invention, the first mixing is preferably: mixing vonoprazan fumarate, a stabilizer, a filler, a binder and a disintegrant (referred to as the second mixing) to obtain a second mixture, and mixing the second mixture with a lubricant.

[0040] In the present invention, the second mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 600 to 1500 rpm, more preferably 800 to 1200 rpm, and the mixing time is preferably 5 to 15 min, more preferably 8 to 12 min.

[0041] In the present invention, the second mixing is preferably mixing A or mixing B; the mixing A is preferably: mixing vonoprazan fumarate, a stabilizer, a filler and a disintegrant (referred to as the third mixing) to obtain a third mixture, and then mixing the third mixture with a binder.

[0042] In the present invention, the third mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 600 to 1500 rpm, more preferably 800 to 1200 rpm, and the mixing time is preferably 5 to 15 min, more preferably 8 to 12 min.

[0043] In the present invention, the mixture B is preferably: a stabilizer and a binder are mixed (referred to as the fourth mixture) to obtain a fourth mixture, vonoprazan fumarate, a filler and a disintegrant are mixed (referred to as the fifth mixture) to obtain a fifth mixture, and then the fourth mixture and the fifth mixture are mixed.

[0044] In the present invention, the fourth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 150 to 300 rpm, more preferably 200 to 250 rpm, and the mixing time is preferably 10 to 30 min, more preferably 15 to 25 min.

[0045] In the present invention, the fifth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 600 to 1500 rpm, more preferably 800 to 1200 rpm, and the mixing time is preferably 5 to 15 min, more preferably 8 to 12 min.

[0046] The present invention also provides a vonoprazan fumarate tablet, comprising a tablet core and a coating layer coated on the surface of the tablet core; the tablet core is the vonoprazan fumarate composition described in the above scheme or the vonoprazan fumarate composition obtained by the preparation method described in the above scheme.

[0047] The vonoprazan fumarate tablets provided by the present invention include a tablet core; the mass percentage of the tablet core in the vonoprazan fumarate tablets is preferably 95.5-97.5%, more preferably 96-97%, and further preferably 96.5%.

[0048] The vonoprazan fumarate tablets provided by the present invention include a coating layer coated on the surface of the tablet core; the mass percentage of the coating layer to the vonoprazan fumarate tablets is preferably 2.5-4.5%, more preferably 3-4%, and further preferably 3.5%.

[0049] In the present invention, the coating layer is preferably prepared from hypromellose, polyethylene glycol, yellow iron oxide, red iron oxide and titanium dioxide. The present invention can play a certain light-shielding effect by adding titanium dioxide to the coating layer, further improving the stability of the drug.

[0050] The present invention also provides a method for preparing the vonolazepam fumarate tablets described in the above scheme, comprising the following steps:

[0051] (1) mixing vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant, a lubricant and water and then tableting to obtain a tablet core;

[0052] (2) coating the tablet core to obtain vonolazepine fumarate raw tablets.

[0053] The present invention is to mix vonoprazan fumarate, stabilizer, filler, binder, disintegrant, lubricant and water (referred to as the sixth mixture) and then tablet to obtain a tablet core. In the present invention, the sixth mixture is preferably: vonoprazan fumarate, stabilizer, filler, binder, disintegrant and water are mixed (referred to as the seventh mixture) to obtain a seventh mixture, the seventh mixture is sequentially granulated, dried and granulated to obtain granules, and the granules are mixed with a lubricant.

[0054] In the present invention, the target particle size of the granulation is preferably 0.6 to 1.7 mm, more preferably 0.85 mm.

[0055] In the present invention, the drying temperature is preferably 40 to 60° C., more preferably 50 to 60° C., further preferably 50 to 55° C., and the heat preservation time is preferably 2.5 to 3 h, more preferably 2.7 h.

[0056] In the present invention, the target particle size of the sized particles is preferably 0.6 to 1.7 mm, more preferably 0.85 mm.

[0057] In the present invention, the seventh mixture is preferably mixture C or mixture D; the mixture C is preferably: mixing vonoprazan fumarate, a stabilizer, a filler and a disintegrant (referred to as the eighth mixture) to obtain an eighth mixture, mixing a binder and water (referred to as the ninth mixture) to obtain a ninth mixture, and then mixing the eighth mixture and the ninth mixture.

[0058] In the present invention, the eighth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 600 to 1500 rpm, more preferably 800 to 1200 rpm, and the mixing time is preferably 5 to 15 min, more preferably 8 to 12 min.

[0059] In the present invention, the ninth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 150 to 300 rpm, more preferably 200 to 250 rpm, and the mixing time is preferably 40 to 60 min, more preferably 45 to 55 min.

[0060] In the present invention, the mixing D is preferably: mixing vonoprazan fumarate, a filler and a disintegrant (referred to as the tenth mixing) to obtain a tenth mixture, mixing a binder, a stabilizer and water (referred to as the eleventh mixing) to obtain an eleventh mixture, and then mixing the tenth mixture and the eleventh mixture.

[0061] In the present invention, the tenth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 600 to 1500 rpm, more preferably 800 to 1200 rpm, and the mixing time is preferably 5 to 15 min, more preferably 8 to 12 min.

[0062] In the present invention, the eleventh mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 150 to 300 rpm, more preferably 200 to 250 rpm, and the mixing time is preferably 10 to 30 min, more preferably 15 to 25 min.

[0063] In the present invention, the eleventh mixing is preferably: mixing the binder and water (referred to as the twelfth mixing) to obtain a binder aqueous solution, and then mixing the binder aqueous solution and a stabilizer.

[0064] In the present invention, the twelfth mixing is preferably stirring mixing; the rotation speed of the stirring mixing is preferably 150 to 300 rpm, more preferably 200 to 250 rpm, and the mixing time is preferably 10 to 30 min, more preferably 15 to 25 min.

[0065] In the present invention, the tableting pressure is preferably 7.50 to 11.00 kg, more preferably 8.00 to 10.50 kg, and the pressure holding time is preferably 2 to 7 s, more preferably 3 to 5 s.

[0066] After obtaining the tablet core, the present invention coats the tablet core to obtain vonoprazan fumarate tablets. In the present invention, the coating is preferably performed by mixing a coating powder and water to obtain a coating solution, and then coating the coating solution on the surface of the tablet core while drying.

[0067] In the present invention, the mass ratio of the coating powder to water is preferably 0.8-1.5:7-12, more preferably 1:9; the coating powder preferably includes hypromellose, polyethylene glycol, yellow iron oxide, red iron oxide and titanium dioxide. In a specific embodiment of the present invention, the coating powder is preferably commercially available

[0068] In the present invention, the coating is preferably spraying; the temperature of the tablet core during the coating is preferably 35-50°C, more preferably 40-45°C, and the coating time is preferably 1.5-3.0h, more preferably 2.0-2.5h. The present invention heats the tablet core to a certain temperature to achieve coating the coating liquid on the surface of the tablet core while drying.

[0069] In order to further illustrate the present invention, the scheme of the present invention is described in detail below in conjunction with embodiments, but they should not be understood as limiting the scope of protection of the present invention.

[0070] Example 1

[0071] The composition of the vonopraz fumarate tablets in this example is shown in Table 1.

[0072] Table 1 Composition of Example 1 Vonola Fumarate Tablets

[0073]

[0074]

[0075] The preparation method of vonola fumarate raw tablets in this embodiment:

[0076] (1) adding tartaric acid to a hydroxypropylcellulose aqueous solution and dissolving it to obtain a tartaric acid-binder aqueous solution;

[0077] (2) mixing vonoprazan fumarate, mannitol, microcrystalline cellulose and croscarmellose sodium to obtain a premixed powder;

[0078] (3) mixing the tartaric acid-binder aqueous solution and the premixed powder, and sequentially granulating, drying and sizing the particles to obtain particles; mixing the particles with a lubricant to obtain intermediate particles;

[0079] (4) tableting the intermediate particles to obtain tablet cores;

[0080] (5) Spraying the tablet core with a coating solution (the mass ratio of coating powder to water is 1:9) to obtain vonolazepine fumarate raw tablets.

[0081] Example 2

[0082] The composition of the vonopraz fumarate tablets in this example is shown in Table 2.

[0083] Table 2 Composition of Example 2 Vonola Fumarate Tablets

[0084]

[0085] The preparation method of vonola fumarate raw tablets in this embodiment:

[0086] (1) adding hydroxypropyl cellulose to purified water to dissolve it to obtain an adhesive aqueous solution;

[0087] (2) mixing vonoprazan fumarate, tartaric acid, lactose, microcrystalline cellulose and cross-linked polyvinylpyrrolidone to obtain a premixed powder;

[0088] (3) mixing the binder aqueous solution and the premixed powder, and sequentially granulating, drying and sizing the particles to obtain particles; mixing the particles with a lubricant to obtain intermediate particles;

[0089] (4) tableting the intermediate particles to obtain tablet cores;

[0090] (5) Spraying the tablet core with a coating solution (the mass ratio of coating powder to water is 1:9) to obtain vonolazepine fumarate raw tablets.

[0091] Example 3

[0092] The composition of the vonopraz fumarate tablets in this example is shown in Table 3.

[0093] Table 3 Composition of Example 3 Vonola Fumarate Tablets

[0094]

[0095] The preparation method of vonola fumarate raw tablets in this embodiment:

[0096] (1) adding tartaric acid to a hydroxypropylcellulose aqueous solution and dissolving it to obtain a tartaric acid-binder aqueous solution;

[0097] (2) mixing vonoprazan fumarate, mannitol, microcrystalline cellulose and croscarmellose sodium to obtain a premixed powder;

[0098] (3) mixing the tartaric acid-binder aqueous solution and the premixed powder, and sequentially granulating, drying and sizing the particles to obtain particles; mixing the particles with a lubricant to obtain intermediate particles;

[0099] (4) tableting the intermediate particles to obtain tablet cores;

[0100] (5) Spraying the tablet core with a coating solution (the mass ratio of coating powder to water is 1:9) to obtain vonolazepine fumarate raw tablets.

[0101] Example 4

[0102] The composition of the vonopraz fumarate tablets in this example is shown in Table 4.

[0103] Table 4 Composition of Example 4 Vonola Fumarate Tablets

[0104]

[0105] The preparation method of vonola fumarate raw tablets in this embodiment:

[0106] (1) adding hydroxypropyl cellulose to purified water to dissolve it to obtain an adhesive aqueous solution;

[0107] (2) mixing vonoprazan fumarate, tartaric acid, lactose, microcrystalline cellulose and cross-linked polyvinylpyrrolidone to obtain a premixed powder;

[0108] (3) mixing the binder aqueous solution and the premixed powder, and sequentially granulating, drying and sizing the particles to obtain particles; mixing the particles with a lubricant to obtain intermediate particles;

[0109] (4) tableting the intermediate particles to obtain tablet cores;

[0110] (5) Spraying the tablet core with a coating solution (the mass ratio of coating powder to water is 1:9) to obtain vonolazepine fumarate raw tablets.

[0111] Comparative Example

[0112] The compositions of the vonolazepam fumarate tablets in Comparative Examples 1-2 are shown in Table 5.

[0113] Table 5 Composition of Comparative Examples 1 to 2 Vonola Fumarate Tablets

[0114]

[0115] The preparation methods of Comparative Examples 1-2 are the same as that of Example 1.

[0116] Test Case

[0117] The stability test of the vonoprazan fumarate tablets prepared in Examples 1 to 4 and Comparative Examples 1 to 2 was performed using the following test method:

[0118] The vonoprazan fumarate tablets prepared in Examples 1 to 4 and Comparative Examples 1 to 2 were placed under the same lighting conditions (4500±500 Lux) for 30 days, and their photodegradation product U-9 was detected at 0 day and 30 days, respectively. The conditions of the high performance liquid chromatography used are shown in Table 6, and the test results are shown in Table 7.

[0119] Table 6 High performance liquid chromatography conditions

[0120]

[0121]

[0122] Table 7 Stability data of vonopraz fumarate tablets of Examples 1 to 4 and Comparative Examples 1 to 2

[0123]

[0124] It can be seen from Table 7 that the voronoprazan fumarate tablets obtained by using stabilizers such as tartaric acid in the present invention have high light stability. This indicates that stabilizers such as tartaric acid as pharmaceutical compositions can provide the same effect of inhibiting the increase of decomposition products as fumaric acid.

[0125] It can be seen from the above examples that the vonoprazan fumarate composition provided by the present invention improves the stability of the drug without changing the acidity of the drug itself.

[0126] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. Other embodiments can be obtained based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. A vonoprazan fumarate composition, It is characterized in that including vonoprazan fumarate, stabilizers, fillers, binders, disintegrants and lubricants; The stabilizer includes one or more of tartaric acid, maleic acid, malonic acid and tartaric acid.

2. The vonoprazan fumarate composition according to claim 1, It is characterized in that Calculated by weight percentage, the vonoprazan fumarate composition comprises 5-15wt% of vonoprazan fumarate, 0.05-1.0wt% of a stabilizer, 70-90wt% of a filler, 1-3wt% of a binder, 2-8wt% of a disintegrant and the remainder of a lubricant.

3. The vonoprazan fumarate composition according to claim 1 or 2, It is characterized in that The binder includes one or more of cellulose, starch and povidone; The cellulose includes one or more of hydroxypropyl cellulose, hydroxypropyl methyl cellulose and carboxymethyl cellulose.

4. A method for preparing the vonoprazan fumarate composition according to any one of claims 1 to 3, It is characterized in that The following steps are involved: The vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant and a lubricant are first mixed to obtain a vonoprazan fumarate composition.

5. The preparation method according to claim 4, It is characterized in that The first mixing comprises: mixing vonoprazan fumarate, a stabilizer, a filler, a binder and a disintegrant to obtain a second mixture, and mixing the second mixture with a lubricant.

6. A vonola fumarate raw tablet, It is characterized in that It comprises a tablet core and a coating layer coated on the surface of the tablet core; The tablet core is the vonoprazan fumarate composition according to any one of claims 1 to 3 or the vonoprazan fumarate composition obtained by the preparation method according to any one of claims 4 to 5.

7. The vonola fumarate raw tablet according to claim 6, It is characterized in that The mass percentage of the tablet core in the vonola raw fumarate tablet is 95.5-97.5%; The coating layer accounts for 2.5-4.5% of the mass of the vonola fumarate raw tablets.

8. A method for preparing the vonola fumarate raw tablets according to any one of claims 6 to 7, It is characterized in that The following steps are involved: (1) mixing vonoprazan fumarate, a stabilizer, a filler, a binder, a disintegrant, a lubricant and water and then tableting to obtain a tablet core; (2) coating the tablet core to obtain vonolazepine fumarate raw tablets.

9. The preparation method according to claim 8, It is characterized in that The tabletting pressure is 7.50-11.00 kg, and the pressure holding time is 2-7 s.

10. The preparation method according to any one of claims 8 to 9, It is characterized in that The coating is performed by mixing coating powder and water to obtain coating solution, and then coating the coating solution on the surface of the tablet core while drying.

Citation Information

Cited By

  • Novel compositions for vonoprazan

    WO2026142512A1